Anti-Factor D Antibody PEGylation for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic antibodies, particularly anti-Factor D antibodies, face challenges in stability and delivery due to their biophysical properties, leading to instability, aggregation, and reduced efficacy when administered in high concentrations, especially in ocular applications where achieving and maintaining bioavailability is difficult.
Innovation Solution
Development of anti-Factor D antibody variants with targeted amino acid substitutions and conjugation to multi-armed polymers like PEG, which improve stability, solubility, and ocular residence time, allowing for high-concentration formulations and long-acting delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high concentration of antibody is administered to achieve desired efficacy, then therapeutic effect is improved, but protein stability deteriorates leading to aggregation and degradation
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical properties of the antibody through PEGylation. The conjugation of polyethylene glycol chains to the antibody molecule changes its hydrodynamic radius, charge distribution, and solvation properties, enabling the antibody to maintain stability at high concentrations (100-500 mg/mL) that would otherwise cause aggregation and precipitation.
Solution Approach 2:
The patent creates a composite material system by chemically conjugating PEG polymers to the antibody protein. This composite structure combines the therapeutic functionality of the antibody with the stabilizing and solubility-enhancing properties of PEG, resulting in a conjugate that resists aggregation and maintains structural integrity at high concentrations.
2Productivity
If high concentration formulation is used to reduce delivery volume, then delivery efficiency is improved, but viscosity increases making injection difficult
Solution Approach 1:
PEGylation changes the hydrodynamic and rheological parameters of the antibody solution. The PEG chains increase the effective volume of individual antibody molecules while creating steric barriers that prevent intermolecular interactions, thereby maintaining low viscosity even at high concentrations suitable for volume-reduced dosing.
3Reliability
If antibody is administered to achieve therapeutic efficacy, then complement inhibition is improved, but immunogenicity increases due to aggregates and degradants
Solution Approach 1:
The patent converts the potential harm of protein instability and aggregation into a benefit by using PEGylation to prevent these issues. The PEG conjugation stabilizes the antibody, reducing degradation and aggregation that would otherwise trigger immune responses, thereby decreasing immunogenicity while maintaining or enhancing therapeutic efficacy.
4Reliability
If frequent dosing is used to maintain bioavailability, then therapeutic effect is maintained, but patient convenience deteriorates
Solution Approach 1:
The patent applies dynamics by creating a dosage form with extended circulation and residence time. The PEG-conjugated antibody exhibits altered pharmacokinetics with prolonged half-life, allowing the therapeutic effect to be maintained over extended periods and enabling less frequent dosing schedules while preserving bioavailability.
Data Source
AI summary
The disclosure relates to antibody-polymer conjugates comprising one or more anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.